- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03750526
Effectiveness of Augmented Reality and Repetitive Transcranial Magnetic Stimulation
December 9, 2019 updated by: Lai chien hung, Taipei Medical University Hospital
Investigate the Effectiveness of Augmented Reality and Repetitive Transcranial Magnetic Stimulation Technology in Persons With Stroke
This study is to investigate the combined effects of repetitive Transcranial Magnetic Stimulation (rTMS) and Augmented Reality (AR) intervention on cortical excitability, balance, gait, activity in individuals with stroke.
Forty participants will be recruited in this study.
They will be allocated to four group: rTMS and AR group (10), sham rTMS and AR group (10), AR group (10), and conventional physiotherapy group (10).
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Participants will be randomized allocated to four groups: rTMS and AR group, sham rTMS and AR group, AR group ,and conventional physiotherapy group in current study.
All participants underwent four weeks, 3 sessions per week, and 60 minutes per session training program.
Motor evoked potential (MEP), Time up go test (TUG), Berg Balance Scale (BBS), Fugl-Meyer Assessment (FMA), Multi-directional Reach Test (MDRT),The Postural Assessment Scale for Stroke Patients (PASS), and Taiwanese Depression Questionnaires (TDQ) will be assessed before and after intervention in all participants.
Study Type
Interventional
Enrollment (Anticipated)
40
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Taipei, Taiwan
- Recruiting
- Taipei Medical University Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 80 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Cognitive ability is sufficient to understand the nature of study (Mini-Mental State Examination score was above 23).
- Participants suffer from unilateral hemiplegia caused by a first-ever stroke.
- Participants are stable in medical and psychological condition.
Exclusion Criteria:
- Participants have other neurologic problems that can affect balance and walking ability.
- Participants take of drugs or have other medical condition that can affect balance and function.
- Participants have contraindications for rTMS intervention such as pacemaker, cochlear implants, metal in the brain or skull, open wound of brain, or history of epilepsy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: rTMS and AR group
Ten participants in group A will undergo repetitive transcranial magnetic stimulation (real, 1 Hz, 15 minutes), follow by a session of augmented reality exercise (45 minutes), 3 days per week for 4 weeks.
|
rTMS performs 1Hz,15 minutes real rTMS.
AR intervention contains weight-shift exercise, strengthening of lower limb and balance training for 45 minutes.
|
Active Comparator: Sham rTMS and AR group
Ten participants in group B will receive repetitive transcranial magnetic stimulation (sham,1 Hz, 15 minutes), follow by a session of augmented reality exercise (45 minutes), 3 days per week for 4 weeks.
|
Sham rTMS applies 1Hz, 15 minutes sham rTMS.
AR intervention includes weight-shift exercise, strengthening of lower limb and balance training for 45 minutes.
|
Active Comparator: AR group
Ten participants in group C will undergo augmented reality exercise 60 minutes a day and 3 days per week for four weeks.
|
AR intervention contains weight-shift exercise, strengthening of lower limb and balance training for 60 minutes.
|
Active Comparator: Conventional physiotherapy group
Ten participants allocated to the group D will receive conventional physiotherapy 60 minutes a day and 3 days per week for four weeks.
|
Conventional physiotherapy includes rolling, sitting, balance exercise, standing, overground walking, facilitation of the paretic limbs, and so on for 60 minutes.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of Time Up Go test (TUG)
Time Frame: Measurement before and after intervention ( week 0 and at the end of week 4) in four groups
|
The TUG test will ask participants to stand up, walk for 3 m, turn, walk back and sit down as fast as they can during the test, and the time requires for each patient to complete the test is recorded.
|
Measurement before and after intervention ( week 0 and at the end of week 4) in four groups
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change of Berg Balance Scale (BBS)
Time Frame: Measurement before and after intervention ( week 0 and at the end of week 4) in four groups
|
Participants performed a series of 14 functional balance tasks, including maintaining a quiet stance, sitting-to-standing, shifting weight and reaching, turning in place, standing on one leg, and maintaining a tandem stance.
Each task was scored on a 5-point ordinal scale (from 0 to 4).
A score of 0 denotes the inability of the participant to perform the task, and a score of 4 denotes that the participant can complete the task based on a preset criterion.
The highest possible score is 56.
|
Measurement before and after intervention ( week 0 and at the end of week 4) in four groups
|
Change of Motor evoked potential (MEP)
Time Frame: Measurement before and after intervention ( week 0 and at the end of week 4) in four groups
|
Motor evoked potential (MEP) is recorded from tibialis anterior muscles following direct transcranial magnetic stimulation (TMS) of motor cortex.
All TMS is delivered with the participant seated upright on the chair.
Both passive and active conditions, participants are instructed to relax their right leg in the seated position.
TMS is delivered over the motor cortex (M1) using a concave double cone coil (Magstim Co., United Kingdom) attached to a BiStim magnetic stimulator (Magstim Co., United Kingdom).
To locate the optimal site, stimuli are delivered over various points along the M1.
The optimal site is the location on the M1 that evoked the greatest MEP amplitude in the bilateral tibialis anterior muscles.
The onset latency and onset to peak amplitude will be assessed.
|
Measurement before and after intervention ( week 0 and at the end of week 4) in four groups
|
Change of Fugl-Meyer Assessment (FMA)-Lower extremity
Time Frame: Measurement before and after intervention ( week 0 and at the end of week 4) in four groups
|
Fugl-Meyer Assessment-Lower extremity is used to measure lower-limb recovery in stroke rehabilitation studies.The scale has 6 items ranging from reflex activity to voluntary motor control.
Each item further comprises components, with a total of 17. Scoring is done on a 3-point ordinal scale ranges from 0 (no performance) to 2 (faultless performance).
The total score range from 0 (no motor function) to 34 (good motor recovery).
|
Measurement before and after intervention ( week 0 and at the end of week 4) in four groups
|
Change of Multi-directional Reach Test (MDRT)
Time Frame: Measurement before and after intervention ( week 0 and at the end of week 4) in four groups
|
Participants will be required to reach in the forward, left and right directions.
The test is performed with the participant in standing.
It is the measure of the difference, in centimeters, between arm's length with arms at 90° flexion/ abduction and maximal forward, left and right directions reaching respectively, using a fixed base of support.
The test uses a centimeters measuring device against a wall at shoulder height.
|
Measurement before and after intervention ( week 0 and at the end of week 4) in four groups
|
Change of The Postural Assessment Scale for Stroke Patients (PASS)
Time Frame: Measurement before and after intervention ( week 0 and at the end of week 4) in four groups
|
The Postural Assessment Scale for Stroke Patients (PASS) is a postural assessment scale specifically designed to assess and monitor postural control after stroke.
It contains 12 four-level items of varying difficulty for assessing ability to maintain or change a given lying, sitting, or standing posture.
The PASS consists of 2 sections with a 4-point scale to describe each task.
The total score ranges from 0 - 36.
A score of 0 denotes the inability of the participant to perform the task, and a score of 3 denotes that the participant can complete the task based on a preset criterion.
The highest possible score is 36.
|
Measurement before and after intervention ( week 0 and at the end of week 4) in four groups
|
Change of Taiwanese Depression Questionnaires (TDQ)
Time Frame: Measurement before and after intervention ( week 0 and at the end of week 4) in four groups
|
Taiwanese Depression Questionnaires (TDQ) contains 18 items to screen the situation of depression within a week.
The TDQ, which is a 4-point scale with 18 items, is a culturally specific depression self-rating instrument for effective screening of depression in Taiwan and has satisfactory reliability and validity.
Subjects are guided to rate each item on a scale from 0 to 3 on the basis of "how often you felt the physical and emotional aspects during the past week".
Zero denotes never, three means always.
TDQ scores range from 0 to 54.
|
Measurement before and after intervention ( week 0 and at the end of week 4) in four groups
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
July 31, 2018
Primary Completion (Anticipated)
October 30, 2020
Study Completion (Anticipated)
December 30, 2020
Study Registration Dates
First Submitted
November 20, 2018
First Submitted That Met QC Criteria
November 20, 2018
First Posted (Actual)
November 23, 2018
Study Record Updates
Last Update Posted (Actual)
December 11, 2019
Last Update Submitted That Met QC Criteria
December 9, 2019
Last Verified
December 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- N201703084
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Stroke
-
University Hospital, GhentRecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Stroke HemorrhagicBelgium
-
Moleac Pte Ltd.RecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, CryptogenicSingapore, Philippines
-
Moleac Pte Ltd.Not yet recruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke, Cardiovascular | Strokes Thrombotic | Stroke, Embolic | Stroke, Cryptogenic
-
IRCCS San Camillo, Venezia, ItalyRecruitingStroke | Stroke, Ischemic | Stroke Sequelae | Stroke HemorrhagicItaly
-
Vanderbilt University Medical CenterPatient-Centered Outcomes Research Institute; University of Alabama at BirminghamEnrolling by invitationStroke | Stroke, Ischemic | Stroke, Acute | Stroke Sequelae | Engagement, Patient | Stroke HemorrhagicUnited States
-
University of MinnesotaAmerican Occupational Therapy FoundationRecruitingStroke | Stroke Sequelae | Stroke Hemorrhagic | Stroke IschemicUnited States
-
University of British ColumbiaCanadian Institutes of Health Research (CIHR); Michael Smith Foundation for...RecruitingStroke | Stroke, Ischemic | Stroke Hemorrhagic | Chronic StrokeCanada
-
University of CincinnatiMedical University of South Carolina; University of California, Los Angeles; University...RecruitingStroke | Stroke, Ischemic | Stroke, Acute | Stroke HemorrhagicUnited States
-
University of LiegeCompletedStroke, Acute | Stroke Hemorrhagic | Stroke, ComplicationBelgium
-
Turkish Stroke Research and Clinical Trials NetworkElectroCore INC; Turkish Neurological SocietyCompletedStroke | Stroke, Ischemic | Stroke, Acute | Stroke, HemorrhagicTurkey
Clinical Trials on rTMS and AR
-
Aerie PharmaceuticalsCompletedDiabetic Macular Edema | Neovascular Age-related Macular DegenerationUnited States
-
San Diego State UniversityNational Institute of Mental Health (NIMH)Completed
-
ALTality, Inc.National Institute on Drug Abuse (NIDA); M.D. Anderson Cancer Center; Baylor...Active, not recruitingSurgery | Pediatric CancerUnited States
-
Aridis Pharmaceuticals, Inc.CompletedStaphylococcus Aureus | Pneumonia, Ventilator-Associated | Infection, Bacterial | Lung InfectionBelarus, Belgium, Brazil, China, Estonia, France, Georgia, Israel, Latvia, Mexico, Russian Federation, South Africa, Spain, Turkey, Ukraine
-
Chang Gung UniversityRecruitingParkinson Disease(PD)Taiwan
-
Aerie PharmaceuticalsCompletedOcular Hypertension | Open Angle GlaucomaUnited States
-
Aerie PharmaceuticalsCompletedElevated Intraocular PressureUnited States
-
Massachusetts General HospitalAmerican Psychological Foundation; The Hilda & Preston Davis FoundationCompletedAvoidant/Restrictive Food Intake Disorder (ARFID)United States